MondegarAI
EcoR1 Capital, LLC

Q1 2025 · 13F-HR

EcoR1 Capital, LLCholdings as filed

Filed 2025-05-15 · accession 0000935836-25-000338

$1.69B
Reported value
46
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$260.2M15.4%11,895,808CommonSOLE
G50871105JAZZJAZZ PHARMACEUTICALS PLC$211.9M12.6%1,706,469CommonSOLE
98985Y108ZYMEZYMEWORKS INC$205.6M12.2%17,259,548CommonSOLE
032724106ANABANAPTYSBIO INC$146.5M8.69%7,880,094CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$143.8M8.53%4,288,120CommonSOLE
G72800108PRTAPROTHENA CORP PLC$143.4M8.50%11,584,280CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$82.5M4.89%1,292,386CommonSOLE
98401F105XNCRXENCOR INC$65.4M3.88%6,144,767CommonSOLE
H17182108CRSPCRISPR THERAPEUTICS AG$47.3M2.80%1,389,276CommonSOLE
N90064101QUREUNIQURE NV$42.3M2.51%3,988,971CommonSOLE
47103J105JANXJANUX THERAPEUTICS INC$39.7M2.35%1,469,818CommonSOLE
45257U108IMNMIMMUNOME INC$27.5M1.63%4,079,415CommonSOLE
29772L108ETONETON PHARMACEUTICALS INC$25.2M1.49%1,939,288CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$24.8M1.47%75,000CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$19.1M1.13%3,418,068CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$17.8M1.06%440,000CommonSOLE
50127T109KURAKURA ONCOLOGY INC$17.4M1.03%2,640,298CommonSOLE
878972108TECXTECTONIC THERAPEUTIC INC$16.6M0.98%935,121CommonSOLE
05370A108RNAGBPAVIDITY BIOSCIENCES INC$16.5M0.98%557,576CommonSOLE
64135M105NGNENEUROGENE INC$14.9M0.88%1,271,342CommonSOLE
87583X109TNGXTANGO THERAPEUTICS INC$14.6M0.86%10,630,736CommonSOLE
92915B106VYGRVOYAGER THERAPEUTICS INC$13.2M0.79%3,917,546CommonSOLE
07373V105BEAMBEAM THERAPEUTICS INC$10.3M0.61%526,685CommonSOLE
55287L101MBXMBX BIOSCIENCES INC$9.3M0.55%1,259,273CommonSOLE
37611X209DNAGINKGO BIOWORKS HOLDINGS INC$8.3M0.49%1,462,328CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$8.3M0.49%850,341CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC$7.7M0.46%910,000CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$6.8M0.41%862,068CommonSOLE
92539P101VERVE THERAPEUTICS INC$5.7M0.34%1,250,000CommonSOLE
00653A107ADAPYADAPTIMMUNE THERAPEUTICS PLC$5.4M0.32%27,404,070CommonSOLE
36315X101LKFTGALAPAGOS NV$3.9M0.23%155,006CommonSOLE
00032Q104WHWKWHITEHAWK THERAPEUTICS INC$3.7M0.22%2,082,000CommonSOLE
046513206ATRAATARA BIOTHERAPEUTICS INC$3.4M0.20%573,183CommonSOLE
83422E204SLDBSOLID BIOSCIENCES INC$2.8M0.16%744,450CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$1.9M0.11%187,500CommonSOLE
67080N119NUVB/WSNUVATION BIO INC$1.7M0.10%963,333CommonSOLE
75943R102RLAYRELAY THERAPEUTICS INC$1.7M0.10%641,426CommonSOLE
482929106KLRSKALARIS THERAPEUTICS INC$1.6M0.10%201,718CommonSOLE
N90064101QUREUNIQURE NV$1.4M0.08%135,000CALLSOLE
74168J101PRMEPRIME MEDICINE INC$1.4M0.08%700,000CommonSOLE
59267L107METSERA INC$1.4M0.08%50,000CommonSOLE
89854M101TCRXTSCAN THERAPEUTICS INC$914,7100.05%662,833CommonSOLE
86889P117SRZNWSURROZEN INC$777,3140.05%66,665CommonSOLE
01626L204ALGSALIGOS THERAPEUTICS INC$730,6940.04%88,569CommonSOLE
29772L108ETONETON PHARMACEUTICALS INC$655,4900.04%50,500CALLSOLE
91678A107UPBUPSTREAM BIO INC$367,2000.02%60,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.